DEXCOM INC — Form 8-K
Filed July 30, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 42/100
What the filing says
Dexcom reported Q2 2026 revenue of $1.308B (13% YoY growth); U.S. revenue grew 11%, international 19%. GAAP operating margin expanded 590 bps to 24.3%; non-GAAP operating margin to 25.1%. The company raised FY2026 revenue guidance to $5.18–$5.25B (11–13% growth) and increased non-GAAP gross profit margin guidance to ~64%, operating margin to ~23.5–24%, and adjusted EBITDA margin to ~31.5–32%. Key strategic wins: positive CONNECT trial results for Stelo in type 2 diabetes without insulin, and Stelo app redesign launch.
Why this rating
Solid execution with margin expansion and guidance raise is encouraging but not transformational. Revenue growth of 11–13% is steady, not accelerating dramatically. Event is ~4% of market cap; meaningful but not trajectory-changing for a $34B company.
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.